Skip to content
10-Q

Quarterly Report

IMPEL PHARMACEUTICALS INC

0000950170-23-021513

← back to feed
Filed
May 12, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 8, 2023 23.75M sh
Shares Diluted Q1 2023 · Mar 31, 2023 23.75M sh
Shares Diluted Q1 2023 · Mar 31, 2022 23.14M sh
Capex Q1 2023 · Mar 31, 2023 $1.05M
Capex Q1 2023 · Mar 31, 2022 $8K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$24.14M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$24.21M
Long Term Debt Q1 2023 · Mar 31, 2023 $48.1M
Long Term Debt Q1 2023 · Dec 31, 2022 $48.07M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $35.47M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $60.65M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$72.91M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$44.16M
Stockholders Equity Q1 2023 · Mar 31, 2022 $27.48M
Stockholders Equity Q1 2023 · Dec 31, 2021 $52.51M
Current Liabilities Q1 2023 · Mar 31, 2023 $22.28M
Current Liabilities Q1 2023 · Dec 31, 2022 $22.16M
Total Liabilities Q1 2023 · Mar 31, 2023 $137.63M
Total Liabilities Q1 2023 · Dec 31, 2022 $132.71M
Current Assets Q1 2023 · Mar 31, 2023 $51.88M
Current Assets Q1 2023 · Dec 31, 2022 $79.81M
Total Assets Q1 2023 · Mar 31, 2023 $64.73M
Total Assets Q1 2023 · Dec 31, 2022 $88.55M
Eps Diluted Q1 2023 · Mar 31, 2023 −$1.27
Eps Diluted Q1 2023 · Mar 31, 2022 −$1.17
Eps Basic Q1 2023 · Mar 31, 2023 −$1.27
Eps Basic Q1 2023 · Mar 31, 2022 −$1.17
Sga Expense Q1 2023 · Mar 31, 2023 $22.04M
Sga Expense Q1 2023 · Mar 31, 2022 $19.8M
Rd Expense Q1 2023 · Mar 31, 2023 $3M
Rd Expense Q1 2023 · Mar 31, 2022 $3.65M
Net Income Q1 2023 · Mar 31, 2023 −$30.07M
Net Income Q1 2023 · Mar 31, 2022 −$26.97M
Operating Income Q1 2023 · Mar 31, 2023 −$24.44M
Operating Income Q1 2023 · Mar 31, 2022 −$22.72M
Gross Profit Q1 2023 · Mar 31, 2023 $2.09M
Gross Profit Q1 2023 · Mar 31, 2022 $726K
Cost Of Revenue Q1 2023 · Mar 31, 2023 $2.29M
Cost Of Revenue Q1 2023 · Mar 31, 2022 $1.03M
Revenue Q1 2023 · Mar 31, 2023 $4.37M
Revenue Q1 2023 · Mar 31, 2022 $1.76M